Polycythemia vera (PV) is a myeloproliferative neoplasm associated with a haematocrit over 45% and a JAK2 mutation (mainly V617F) [90,91], with phlebotomy being the commonest treatment to lower the haematocrit in lower-risk patients. Here, JAK2 is linked to acquired polycythemia vera.